Opiate neuropharmacology is incredibly complex, as shagnasty and others have already pointed out. I actually studied it for a few months under Sol Snyder, the Guru of Opiates, years ago and learned a bit. And it’s gotten more complex since then!
Basically, you got your kappa, lambda, and mu opiate receptors. Each opiate molecule has different affinities for these receptors, and one type may block one type of receptor while activating another, while ignoring the third, or some other permutation. Effect of the drug varies depending on what it’s doing simultaneously at each receptor site, how long it’s bonded there, and whether or not it’s bonded strongly enough to prevent other opiates from bonding there.
Then you got your opiates which need to be metabolized before they cross the blood-brain barrier, or after they cross, or both, or neither. You have some that cross the barrier in seconds, others may take hours.
Then there’s the opiates that are active as euphoric drugs and pain relievers in their primary form, that get metabolized slowly to another form where they may be more potent, less potent, or even antagonistic to the euphoria and/or the pain response.
Then you have to figure out the route of the drug: Taken in pill or liquid form by mouth, injected into a muscle, injected into a vein, injected just under the skin, inserted rectally, absorbed thru the skin in patch form, or even inhaled, snorted, or used as eye drops. Also injected directly into the central nervous system via a catheter either into or just outside of the spinal canal sac, or infused directly into one of the ventricles of the brain.
Then you should take into account other unrelated drugs that may be in the system at the same time which may either potentiate or diminish the pain-relieving effects of the drug, such as antihistamines, benzodiazepines, stimulants, etc.
All those equivalency tables regarding comparable pain-relieving doses are some rough guidelines based on very subjective reporting by a few handfuls of test patients. Useful as a rough guide in general, but not to be relied on real strongly in any individual situation.
There’s still a lot to be learned. I always remember that heroin was originally designed and marketed to be a non-addicting substitute for morphine, a good pain relieve but a horrible scourge for the addicted and their families. That didn’t pan out. Then demerol was pitched the same way, and look what happened. The same for the mixed agonists/antagonist drugs like talwin (remember T’s and blues, the poor man’s heroin?), stadol, and nubain. And lately, tramadol (ultram) was pushed as a safe alternative to narcotic pain killers. Well, it ain’t.